A completed phase II clinical trial, referred to as NCT00019084, evaluated the efficacy of P53 or RAS peptide vaccines, either independently or in combination with the patient’s own peptide-activated lymphocytes and subcutaneous administration of interleukin-2, a cytokine that enhances the immune response in cancer therapy [106,107]. This evidence concerns the gene TP53 and cancer.